[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630376":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":44,"collaborators":47,"id":51,"slug":19,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":19,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":19,"overallStatus":74,"whyStopped":19,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Miami","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Emapalumab","EXPERIMENTAL","Participants will receive emapalumab administered intravenously at a dose of 6 mg\u002Fkg on Day 1, followed by 3 mg\u002Fkg every 3 days for 2 weeks, and then 3 mg\u002Fkg twice weekly for an additional 2 weeks. Total treatment duration is 12 weeks.",[13],"Drug: Emapalumab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Emapalumab administered intravenously according to the following dosing regimen: 6 mg\u002Fkg on Day 1, followed by 3 mg\u002Fkg every 3 days for 2 weeks, and then 3 mg\u002Fkg twice weekly for 2 weeks.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Kelly Corbitt, D.O.","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","305-243-7545","KKC51@miami.edu",[30],{"facility":31,"status":19,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"University of Miami Hospital and Clinics","Miami","Florida","33136","United States",{"type":37,"coordinates":38},"Point",[39,40],-80.19366,25.77427,{"lat":40,"lon":39},[43],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},{"type":23,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Kelly Corbitt","Assistant Professor of Clinical Medicine",[48],{"name":49,"class":50},"Swedish Orphan Biovitrum","INDUSTRY","100630376",false,"NCT07486869","Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study","Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease","Inclusion Criteria:\n\n* Progressive interstitial lung disease as determined by at least 2\u002F4 of the following:\n\n  1. worsening respiratory symptoms;\n  2. worsening or new oxygen requirement;\n  3. worsening disease on CT chest;\n  4. worsening Forced Vital Capacity (FVC1) or Diffusing Capacity for Carbon Monoxide (DLCO) on pulmonary function tests\n* MDA5 antibodies present\n* Elevated ferritin above the upper limit of normal (ULN)\n* Participant at least 18 years old\n\nExclusion Criteria:\n\n* Active, untreated bacterial, mycobacterial or fungal infection\n* Active herpes zoster infection\n* Currently requiring extracorporeal membrane oxygenation (ECMO)\n* Participant refusal to participate in the study\n* Pregnant women\n* Prisoners","ALL","18 Years",{"count":60,"type":61},5,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.",[67,68,69,70,71,72,73],"Dermatomyositis","Dermatomyositis Sine Myositis","Dermatomyositis With Myopathy","Dermatomyositis With Respiratory Involvement","Dermatomyositis With Organ Involvement","Interstitial Lung Disease","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)","NOT_YET_RECRUITING","2026-06-16",{"date":77,"type":78},"2026-06-18","ACTUAL",{"date":80,"type":61},"2026-07",{"date":82,"type":61},"2027-05",{"name":5,"class":6},1]